New drug duo aims to slash leukemia relapse after bone marrow transplant

This study tests whether adding two drugs, ruxolitinib and decitabine, to the standard chemotherapy given before a stem cell transplant can lower the chance of leukemia returning in high-risk patients. About 200 adults and teens with acute myeloid leukemia in first remission will be randomly assigned to receive either the enhanced or standard pre-transplant regimen. The main goal is to see if the new combination improves survival without relapse or severe graft-versus-host disease.